Screener
Palvella Therapeutics PVLA Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax benefit (expense) | — | — |
| Net loss | $(15,767) | $(8,185) |
| Other comprehensive loss: | ||
| Unrealized gain on investments | 4 | — |
| Foreign currency translation gain (loss) | 8 | (6) |
| Comprehensive loss | $(15,755) | $(8,191) |
| Net loss per share of Common Stock – basic and diluted | $(1.20) | $(0.74) |
| Weighted-average shares used in computing net loss per share of Common Stock – basic and diluted | 13,085,271 | 11,013,697 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Palvella Therapeutics (PVLA) reported comprehensive income (loss), net of tax, attributable to parent of -$15.76M in Q1 2026.
- How has Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 92.3% year-over-year, from -$8.19M to -$15.76M.
- What is the long-term trend for Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 2 years (2021 to 2025), Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a -3.4% compound annual growth rate (CAGR), from -$44.61M to -$41.64M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This is a comprehensive measure of financial performance that includes both net income and other items that bypass the income statement, such as foreign currency translation adjustments. It provides a broader view of the total change in equity resulting from non-owner sources during a specific period. Investors use this to assess the total economic impact of all financial activities on shareholder value.
Ask your AI about Palvella Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude